{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:39:53Z","timestamp":1792532393821,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"IBM Corporation","award":["#1871943"],"award-info":[{"award-number":["#1871943"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"DOI":"10.1007\/s10822-026-00963-7","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T08:53:03Z","timestamp":1792486383000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrative computational analysis of glycan and ROS-linker effects on Pertuzumab-HER2 stability for multimodal ADC architectures"],"prefix":"10.1007","volume":"40","author":[{"given":"Heather A.","family":"Noriega","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang Simon","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"issue":"20","key":"963_CR1","doi-asserted-by":"publisher","first-page":"5552","DOI":"10.1158\/1078-0432.CCR-13-0518","volume":"19","author":"O Metzger-Filho","year":"2013","unstructured":"Metzger-Filho O, Winer EP, Krop I (2013) Pertuzumab: optimizing HER2 blockade. Clin Cancer Res 19(20):5552\u20135556. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0518","journal-title":"Clin Cancer Res"},{"issue":"3","key":"963_CR2","doi-asserted-by":"publisher","first-page":"e41590","DOI":"10.1016\/j.heliyon.2024.e41590","volume":"11","author":"H Ma","year":"2025","unstructured":"Ma H, Li J (2025) Impact of HER2-targeting antibody drug conjugates in treatment strategies for patients with breast cancer. Heliyon 11(3):e41590. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e41590","journal-title":"Heliyon"},{"issue":"4","key":"963_CR3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","volume":"21","author":"SM Swain","year":"2020","unstructured":"Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Montazeri K, Clark E, Knott A, Restuccia E, O\u2019Shaughnessy J, Baselga J (2020) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol 21(4):519\u2013530. https:\/\/doi.org\/10.1016\/S1470-2045(19)30863-0","journal-title":"Lancet Oncol"},{"issue":"2","key":"963_CR4","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1703643","volume":"377","author":"G von Minckwitz","year":"2017","unstructured":"von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G et al (2017) Adjuvant Pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 377(2):122\u2013131. https:\/\/doi.org\/10.1056\/NEJMoa1703643","journal-title":"N Engl J Med"},{"issue":"12","key":"963_CR5","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/S1470-2045(17)30717-9","volume":"18","author":"M Martin","year":"2017","unstructured":"Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H et al (2017) Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 18(12):1688\u20131700. https:\/\/doi.org\/10.1016\/S1470-2045(17)30717-9","journal-title":"Lancet Oncol"},{"issue":"4","key":"963_CR6","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1001\/jamaoncol.2020.7932","volume":"7","author":"HS Rugo","year":"2021","unstructured":"Rugo HS, Im S-A, Cardoso F, Cort\u00e9s J, Curigliano G, Musolino A et al (2021) Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial. JAMA Oncol 7(4):573\u2013584. https:\/\/doi.org\/10.1001\/jamaoncol.2020.7932","journal-title":"JAMA Oncol"},{"issue":"9","key":"963_CR7","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","volume":"28","author":"R Bartsch","year":"2022","unstructured":"Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider-Schur S et al (2022) Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med 28(9):1840\u20131847. https:\/\/doi.org\/10.1038\/s41591-022-01935-8","journal-title":"Nat Med"},{"issue":"25","key":"963_CR8","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang Y-J, Iwasa S, Sugimoto N, Ryu M-H, Sakai D, Chung H-C et al (2020) Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med 382(25):2419\u20132430. https:\/\/doi.org\/10.1056\/NEJMoa2004413","journal-title":"N Engl J Med"},{"key":"963_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.breast.2022.10.016","volume":"66","author":"E Rassy","year":"2022","unstructured":"Rassy E, Rached L, Pistilli B (2022) Antibody drug conjugates targeting HER2: clinical development in metastatic breast cancer. Breast 66:217\u2013226. https:\/\/doi.org\/10.1016\/j.breast.2022.10.016","journal-title":"Breast"},{"issue":"1","key":"963_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E et al (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387(1):9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690","journal-title":"N Engl J Med"},{"issue":"9","key":"963_CR11","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1084\/jem.20130088","volume":"210","author":"Y Bulliard","year":"2013","unstructured":"Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S, Knee DA, Wilson NS, Dranoff G, Brogdon JL (2013) Activating Fc \u03b3 receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med 210(9):1685\u20131693. https:\/\/doi.org\/10.1084\/jem.20130088","journal-title":"J Exp Med"},{"issue":"2","key":"963_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ccr.2004.06.022","volume":"6","author":"Y Nagata","year":"2004","unstructured":"Nagata Y, Lan K-H, Zhou X, Hortobagyi GN, Hung M-C, Yu D et al (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6(2):117\u2013127. https:\/\/doi.org\/10.1016\/j.ccr.2004.06.022","journal-title":"Cancer Cell"},{"issue":"24","key":"963_CR13","doi-asserted-by":"publisher","first-page":"6784","DOI":"10.1158\/1078-0432.CCR-12-1785","volume":"18","author":"S Chandarlapaty","year":"2012","unstructured":"Chandarlapaty S, Sakr RA, Giri D, Patil S, Heguy A, Morrow M et al (2012) Frequent mutational activation of the PI3K\u2013AKT pathway in trastuzumab-resistant breast cancer. Clin Cancer Res 18(24):6784\u20136791. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1785","journal-title":"Clin Cancer Res"},{"key":"963_CR14","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature05474","volume":"445","author":"NV Sergina","year":"2007","unstructured":"Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM et al (2007) Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445:437\u2013441. https:\/\/doi.org\/10.1038\/nature05474","journal-title":"Nature"},{"key":"963_CR15","doi-asserted-by":"publisher","first-page":"175883592513324","DOI":"10.1177\/17588359251332473","volume":"17","author":"A Medhus","year":"2025","unstructured":"Medhus A, Schink KO, Longva AS, Engebraaten O, Berg K, Weyergang A (2025) The mechanisms of HER2 targeted ADCs are dependent on Rab GTPases. Therapeutic Adv Med Oncol 17:17588359251332473. https:\/\/doi.org\/10.1177\/17588359251332473","journal-title":"Therapeutic Adv Med Oncol"},{"key":"963_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12967-025-06082-5","volume":"23","author":"R Huang","year":"2025","unstructured":"Huang R, Hu A, Rong Q, Shu D, Chen M, Yang W et al (2025) Impacts of genomic alterations on the efficacy of HER2-targeted antibody\u2013drug conjugates in patients with metastatic breast cancer. J Translational Med 23:63. https:\/\/doi.org\/10.1186\/s12967-025-06082-5","journal-title":"J Translational Med"},{"issue":"4","key":"963_CR17","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.resinv.2025.05.012","volume":"63","author":"Y Murase","year":"2025","unstructured":"Murase Y, Nanjo S, Ueda T, Liu Y, Nomura S, Arai S, Terada N, Koba H, Tambo Y, Yano S (2025) Mechanisms of resistance to antibody-drug conjugates in cancers. Respiratory Invest 63(4):693\u2013698. https:\/\/doi.org\/10.1016\/j.resinv.2025.05.012","journal-title":"Respiratory Invest"},{"issue":"18","key":"963_CR18","doi-asserted-by":"publisher","first-page":"e172156","DOI":"10.1172\/JCI172156","volume":"133","author":"HL Chang","year":"2023","unstructured":"Chang HL, Schwettmann B, McArthur HL, Chan IS (2023) Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response. J Clin Investig 133(18):e172156. https:\/\/doi.org\/10.1172\/JCI172156","journal-title":"J Clin Investig"},{"issue":"5","key":"963_CR19","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, Goetsch L, Dumontet C, Corva\u00efa N (2017) Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discovery 16(5):315\u2013337. https:\/\/doi.org\/10.1038\/nrd.2016.268","journal-title":"Nat Rev Drug Discovery"},{"key":"963_CR20","doi-asserted-by":"publisher","first-page":"7677","DOI":"10.1038\/s41598-022-11648-0","volume":"12","author":"R Evans","year":"2022","unstructured":"Evans R, Thurber GM (2022) Design of high avidity and low affinity antibodies for in situ control of antibody drug conjugate targeting. Sci Rep 12:7677. https:\/\/doi.org\/10.1038\/s41598-022-11648-0","journal-title":"Sci Rep"},{"issue":"7","key":"963_CR21","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nbt.3212","volume":"33","author":"RP Lyon","year":"2015","unstructured":"Lyon RP, Bovee TD, Doronina SO, Burke PJ, Hunter JH, Neff-LaFord HD, Jonas M, Anderson ME, Setter JR, Senter PD (2015) Reducing hydrophobicity of homogeneous antibody-drug conjugates by engineering branched monomethyl auristatin E linkers. Nat Biotechnol 33(7):733\u2013735. https:\/\/doi.org\/10.1038\/nbt.3212","journal-title":"Nat Biotechnol"},{"key":"963_CR22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y (2022) Antibody drug conjugate: the biological missile for targeted cancer therapy. Signal Transduct Target Therapy 7:93. https:\/\/doi.org\/10.1038\/s41392-022-00947-7","journal-title":"Signal Transduct Target Therapy"},{"key":"963_CR23","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s42004-025-01491-5","volume":"8","author":"B Parshad","year":"2025","unstructured":"Parshad B, Arora S, Singh B, Pan Y, Tang J, Hu Z et al (2025) Towards precision medicine using biochemically triggered cleavable conjugation. Commun Chem 8:100. https:\/\/doi.org\/10.1038\/s42004-025-01491-5","journal-title":"Commun Chem"},{"issue":"7","key":"963_CR24","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/nbt.2289","volume":"30","author":"PD Senter","year":"2012","unstructured":"Senter PD, Sievers EL (2012) The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 30(7):631\u2013637. https:\/\/doi.org\/10.1038\/nbt.2289","journal-title":"Nat Biotechnol"},{"issue":"6","key":"963_CR25","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","volume":"16","author":"MCA Palanca-Wessels","year":"2015","unstructured":"Palanca-Wessels MCA, Czuczman M, Salles G, Assouline S, Sehn LH, Flinn I et al (2015) Safety and activity of the anti-CD79B antibody\u2013drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol 16(6):704\u2013715. https:\/\/doi.org\/10.1016\/S1470-2045(15)70128-2","journal-title":"Lancet Oncol"},{"issue":"13","key":"963_CR26","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1039\/d2cc06677g","volume":"59","author":"N Ashman","year":"2023","unstructured":"Ashman N, Bargh JD, Walsh SJ, Greenwood RD, Tiberghien A, Carroll JS, Spring DR (2023) Peroxide-cleavable linkers for antibody-drug conjugates. Chem Commun 59(13):1841\u20131844. https:\/\/doi.org\/10.1039\/d2cc06677g","journal-title":"Chem Commun"},{"issue":"1","key":"963_CR27","doi-asserted-by":"publisher","first-page":"1600124","DOI":"10.1002\/advs.201600124","volume":"4","author":"G Saravanakumar","year":"2017","unstructured":"Saravanakumar G, Kim J, Kim WJ (2017) Reactive-oxygen-species-responsive drug delivery systems: promises and challenges. Adv Sci 4(1):1600124. https:\/\/doi.org\/10.1002\/advs.201600124","journal-title":"Adv Sci"},{"key":"963_CR28","doi-asserted-by":"publisher","DOI":"10.26434\/chemrxiv-2021-qh8zd","author":"P Gois","year":"2021","unstructured":"Gois P, Ant\u00f3nio J, Carvalho J, Andr\u00e9 A, Dias J, Faustino H et al (2021) Development of diazaborines as ROS sensitive linkers for the construction of stimuli-responsive antibody drug conjugates. ChemRxiv. https:\/\/doi.org\/10.26434\/chemrxiv-2021-qh8zd","journal-title":"ChemRxiv"},{"issue":"5","key":"963_CR29","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10928-023-09884-6","volume":"51","author":"B Scheuher","year":"2024","unstructured":"Scheuher B, Ghusinga KR, McGirr K, Nowak M, Panday S, Apgar J, Subramanian K, Betts A (2024) Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs). J Pharmacokinet Pharmacodyn 51(5):429\u2013447. https:\/\/doi.org\/10.1007\/s10928-023-09884-6","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"12","key":"963_CR30","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1158\/0008-5472.CAN-14-0728","volume":"74","author":"C Bull","year":"2014","unstructured":"Bull C, Stoel MA, den Brok MH, Adema GJ (2014) Sialic acids sweeten a tumor\u2019s life. Cancer Res 74(12):3199\u20133204. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-0728","journal-title":"Cancer Res"},{"issue":"12","key":"963_CR31","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/s41589-020-0622-x","volume":"16","author":"MA Gray","year":"2020","unstructured":"Gray MA, Stanczak MA, Mantuano NR, Xiao H, Pijnenborg JFA, Malaker SA, Miller CL, Weidenbacher PA, Tanzo JT, Ahn G, Woods EC, L\u00e4ubli H, Bertozzi CR (2020) Targeted glycan degradation potentiates the anticancer immune response in vivo. Nat Chem Biol 16(12):1376\u20131384. https:\/\/doi.org\/10.1038\/s41589-020-0622-x","journal-title":"Nat Chem Biol"},{"issue":"9","key":"963_CR32","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nrc3982","volume":"15","author":"SS Pinho","year":"2015","unstructured":"Pinho SS, Reis CA (2015) Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer 15(9):540\u2013555. https:\/\/doi.org\/10.1038\/nrc3982","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"963_CR33","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1021\/acschembio.5b00501","volume":"10","author":"C B\u00fcll","year":"2015","unstructured":"B\u00fcll C, Heise T, Beurskens DMH, Riemersma M, Ashikov A, Rutjes FPJT, van Kuppevelt TH, Lefeber DJ, den Brok MH, Adema GJ, Boltje TJ (2015) Sialic acid glycoengineering using an unnatural sialic acid for the detection of sialoglycan biosynthesis defects and on-cell synthesis of Siglec ligands. ACS Chem Biol 10(10):2353\u20132363. https:\/\/doi.org\/10.1021\/acschembio.5b00501","journal-title":"ACS Chem Biol"},{"issue":"1","key":"963_CR34","doi-asserted-by":"publisher","first-page":"2149057","DOI":"10.1080\/19420862.2022.2149057","volume":"15","author":"ML Jaramillo","year":"2022","unstructured":"Jaramillo ML, Sulea T, Durocher Y, Acchione M, Schur MJ, Robotham A, Kelly JF, Goneau M-F, Robert A, Cepero-Donates Y, Gilbert M (2022) A glyco-engineering approach for site-specific conjugation to Fab glycans. mAbs 15(1):2149057. https:\/\/doi.org\/10.1080\/19420862.2022.2149057","journal-title":"mAbs"},{"issue":"12","key":"963_CR35","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1093\/glycob\/cwp115","volume":"19","author":"J Du","year":"2009","unstructured":"Du J, Meledeo MA, Wang Z, Khanna HS, Paruchuri VDP, Yarema KJ (2009) Metabolic glycoengineering: sialic acid and beyond. Glycobiology 19(12):1382\u20131401. https:\/\/doi.org\/10.1093\/glycob\/cwp115","journal-title":"Glycobiology"},{"issue":"11","key":"963_CR36","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1002\/tcr.202100054","volume":"21","author":"S Manabe","year":"2021","unstructured":"Manabe S, Yamaguchi Y (2021) Antibody glycoengineering and homogeneous antibody\u2013drug conjugate preparation. Chem Record 21(11):3005\u20133014. https:\/\/doi.org\/10.1002\/tcr.202100054","journal-title":"Chem Record"},{"key":"963_CR37","unstructured":"Optimum Strategic Communications (2025), March 28 What to expect at AACR 2025: Heidelberg Pharma to present data from its ADC technology platforms. ADC Review. Retrieved August 18, 2025, from https:\/\/www.adcreview.com\/conference-what-to-expect\/what-to-expect-at-aacr-2025-heidelberg-pharma-to-present-data-from-its-adc-technology-platforms\/"},{"key":"963_CR38","doi-asserted-by":"publisher","first-page":"863118","DOI":"10.3389\/fchem.2022.863118","volume":"10","author":"K Dammen-Brower","year":"2022","unstructured":"Dammen-Brower K, Epler P, Zhu S, Bernstein ZJ, Stabach PR, Braddock DT, Spangler JB, Yarema KJ (2022) Strategies for glycoengineering therapeutic proteins. Front Chem 10:863118. https:\/\/doi.org\/10.3389\/fchem.2022.863118","journal-title":"Front Chem"},{"key":"963_CR39","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3389\/fimmu.2017.00877","volume":"8","author":"G Dekkers","year":"2017","unstructured":"Dekkers G, Treffers L, Plomp R, Bentlage AEH, de Boer M, Koeleman CAM et al (2017) Decoding the human immunoglobulin G-glycan repertoire reveals a spectrum of Fc-receptor- and complement-mediated effector activities. Front Immunol 8:877. https:\/\/doi.org\/10.3389\/fimmu.2017.00877","journal-title":"Front Immunol"},{"key":"963_CR40","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson J, Adler J, Dunger J, Evans R, Green T, Pritzel A et al (2024) Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630:493\u2013500. https:\/\/doi.org\/10.1038\/s41586-024-07487-w","journal-title":"Nature"},{"key":"963_CR41","doi-asserted-by":"publisher","DOI":"10.1101\/2025.05.08.652828","author":"OC Grant","year":"2025","unstructured":"Grant OC, Wentworth D, Holmes SG, Kandel R, Sehnal D, Wang X, Xiao Y, Sheppard P, Grelsson T, Coulter A, Miller G, Foley BL, Woods RJ (2025) Generating 3D models of carbohydrates with GLYCAM-Web. bioRxiv. https:\/\/doi.org\/10.1101\/2025.05.08.652828","journal-title":"bioRxiv"},{"issue":"25","key":"963_CR42","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1002\/jcc.23354","volume":"34","author":"J Huang","year":"2013","unstructured":"Huang J, MacKerell AD Jr. (2013) CHARMM36 all-atom additive protein force field: Validation based on comparison to NMR data. J Comput Chem 34(25):2135\u20132145. https:\/\/doi.org\/10.1002\/jcc.23354","journal-title":"J Comput Chem"},{"issue":"12","key":"963_CR43","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1021\/ci300363c","volume":"52","author":"K Vanommeslaeghe","year":"2012","unstructured":"Vanommeslaeghe K, MacKerell AD Jr. (2012) Automation of the CHARMM general force field (CGenFF) I: bond perception and atom typing. J Chem Inf Model 52(12):3144\u20133154. https:\/\/doi.org\/10.1021\/ci300363c","journal-title":"J Chem Inf Model"},{"key":"963_CR44","doi-asserted-by":"publisher","unstructured":"Corso G, St\u00e4rk H, Jing B, Barzilay R, Jaakkola T (2023) DiffDock: Diffusion steps, twists, and turns for molecular docking. arXiv [Preprint]. International conference on learning representations (ICLR 2023). https:\/\/doi.org\/10.48550\/arXiv.2210.01776","DOI":"10.48550\/arXiv.2210.01776"},{"key":"963_CR45","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","volume":"1\u20132","author":"MJ Abraham","year":"2015","unstructured":"Abraham MJ, Murtola T, Schulz R, P\u00e1ll S, Smith JC, Hess B, Lindahl E (2015) GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1\u20132:19\u201325. https:\/\/doi.org\/10.1016\/j.softx.2015.06.001","journal-title":"SoftwareX"},{"issue":"12","key":"963_CR46","doi-asserted-by":"publisher","first-page":"124105","DOI":"10.1063\/1.2978177","volume":"129","author":"MR Shirts","year":"2008","unstructured":"Shirts MR, Chodera JD (2008) Statistically optimal analysis of samples from multiple equilibrium states. J Chem Phys 129(12):124105. https:\/\/doi.org\/10.1063\/1.2978177","journal-title":"J Chem Phys"},{"issue":"35","key":"963_CR47","doi-asserted-by":"publisher","first-page":"9535","DOI":"10.1021\/jp0217839","volume":"107","author":"S Boresch","year":"2003","unstructured":"Boresch S, Tettinger F, Leitgeb M, Karplus M (2003) Absolute binding free energies: a quantitative approach for their calculation. J Phys Chem B 107(35):9535\u20139551. https:\/\/doi.org\/10.1021\/jp0217839","journal-title":"J Phys Chem B"},{"issue":"19","key":"963_CR48","doi-asserted-by":"publisher","first-page":"6825","DOI":"10.1073\/pnas.0409005102","volume":"102","author":"H-J Woo","year":"2005","unstructured":"Woo H-J, Roux B (2005) Calculation of absolute protein\u2013ligand binding free energy from computer simulations. Proc Natl Acad Sci USA 102(19):6825\u20136830. https:\/\/doi.org\/10.1073\/pnas.0409005102","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"963_CR49","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.bpj.2020.05.020","volume":"119","author":"J Duan","year":"2020","unstructured":"Duan J, Lupyan D, Wang L (2020) Improving the accuracy of protein thermostability predictions for single point mutations. Biophys J 119(1):115\u2013127. https:\/\/doi.org\/10.1016\/j.bpj.2020.05.020","journal-title":"Biophys J"},{"issue":"1","key":"963_CR50","doi-asserted-by":"publisher","first-page":"12489","DOI":"10.1038\/s41598-022-14443-z","volume":"12","author":"F Zhu","year":"2022","unstructured":"Zhu F, Bourguet FA, Bennett WFD, Lau EY, Arrildt KT, Segelke BW et al (2022) Large-scale application of free energy perturbation calculations for antibody design. Sci Rep 12(1):12489. https:\/\/doi.org\/10.1038\/s41598-022-14443-z","journal-title":"Sci Rep"},{"issue":"1","key":"963_CR51","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/pro.3235","volume":"27","author":"TD Goddard","year":"2018","unstructured":"Goddard TD, Huang CC, Meng EC, Pettersen EF, Couch GS, Morris JH, Ferrin TE (2018) UCSF ChimeraX: meeting modern challenges in visualization and analysis. Protein Sci 27(1):14\u201325. https:\/\/doi.org\/10.1002\/pro.3235","journal-title":"Protein Sci"},{"key":"963_CR52","unstructured":"NVIDIA Corporation (2025), July 16 NVIDIA NIM for DiffDock [Software documentation]. Retrieved August 19, 2025, from https:\/\/docs.nvidia.com\/nim\/bionemo\/diffdock\/latest\/index.html"},{"issue":"10","key":"963_CR53","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1021\/acs.jcim.7b00237","volume":"57","author":"R Danne","year":"2017","unstructured":"Danne R, Poojari C, Martinez-Seara H, Rissanen S, Lolicato F, R\u00f3g T, Vattulainen I (2017) doGlycans: tools for preparing carbohydrate structures for atomistic simulations of glycoproteins, glycolipids, and carbohydrate polymers for GROMACS. J Chem Inf Model 57(10):2401\u20132406. https:\/\/doi.org\/10.1021\/acs.jcim.7b00237","journal-title":"J Chem Inf Model"},{"issue":"2","key":"963_CR54","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1021\/acs.jctc.1c00534","volume":"18","author":"RD Lazar","year":"2022","unstructured":"Lazar RD, Akher FB, Ravenscroft N, Kuttel MM (2022) Carbohydrate force fields: the role of small partial atomic charges in preventing conformational collapse. J Chem Theory Comput 18(2):1156\u20131172. https:\/\/doi.org\/10.1021\/acs.jctc.1c00534","journal-title":"J Chem Theory Comput"},{"issue":"4","key":"963_CR55","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.jmb.2007.06.002","volume":"371","author":"DL Mobley","year":"2007","unstructured":"Mobley DL, Graves AP, Chodera JD, McReynolds AC, Shoichet BK, Dill KA (2007) Predicting absolute ligand binding free energies to a simple model site. J Mol Biol 371(4):1118\u20131134. https:\/\/doi.org\/10.1016\/j.jmb.2007.06.002","journal-title":"J Mol Biol"},{"issue":"21","key":"963_CR56","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","volume":"10","author":"FM Veronese","year":"2005","unstructured":"Veronese FM, Pasut G (2005) PEGylation, successful approach to drug delivery. Drug Discovery Today 10(21):1451\u20131458. https:\/\/doi.org\/10.1016\/S1359-6446(05)03575-0","journal-title":"Drug Discovery Today"},{"issue":"3","key":"963_CR57","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nrd1033","volume":"2","author":"JM Harris","year":"2003","unstructured":"Harris JM, Chess RB (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discovery 2(3):214\u2013221. https:\/\/doi.org\/10.1038\/nrd1033","journal-title":"Nat Rev Drug Discovery"},{"key":"963_CR58","doi-asserted-by":"publisher","first-page":"46347","DOI":"10.1038\/srep46347","volume":"7","author":"C Luo","year":"2017","unstructured":"Luo C, Chen S, Xu N, Wang C, Sai WB, Zhao W et al (2017) Glycoengineering of Pertuzumab and its impact on the pharmacokinetic\/pharmacodynamic properties. Sci Rep 7:46347. https:\/\/doi.org\/10.1038\/srep46347","journal-title":"Sci Rep"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-026-00963-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10822-026-00963-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-026-00963-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:03:25Z","timestamp":1792530205000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10822-026-00963-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["963"],"URL":"https:\/\/doi.org\/10.1007\/s10822-026-00963-7","relation":{},"ISSN":["1573-4951"],"issn-type":[{"value":"1573-4951","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"25 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval of the research protocol by an Institutional Review Board: N\/A.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"258"}}